Press "Enter" to skip to content

Exclusive Report on Glucagon like Peptide 1 (GLP – 1) Agonists Market 2019 | Industry Drivers, Business Plans, Types, Applications, Challenges, Opportunities and Latest Trends Forecast to 2024

Glucagon

The “Glucagon like Peptide 1 (GLP – 1) Agonists Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Glucagon like Peptide 1 (GLP – 1) Agonists industry. The information available in the Glucagon like Peptide 1 (GLP – 1) Agonists market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Glucagon like Peptide 1 (GLP – 1) Agonists market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Glucagon like Peptide 1 (GLP – 1) Agonists Market:

  • NovoNordisk
  • Sanofi
  • Eli Lilly
  • AstraZeneca

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999732

    Market Overview:

  • The glucagon-like peptide-1 (GLP-1) agonists market is expected to see a considerable amount of growth during the forecast period. The increase is mainly attributed to the improved efficiency of GLP-1.
  • Increasing diabetes prevalence in established and emerging countries is expected to drive the market. The increase in the diabetic population over the years is due to the overall effect of individual-level factors, like the increasing median age of the population and health factors, including increasing rates of obesity and inactivity levels among people.
  • In addition, lowering birth rates, along with increasing life expectancy, in countries like Japan, Italy, Germany, and France which have a high percentage of the geriatric population, are expected to drive the growth of the market.Novo Nordisk Victoza held a 55% market share in the GLP-1 agonist market in 2017, but it is expected that Eli Lilly’s Trulicity will dominate the market during the forecast period.

    Scope of the Report:

  • The market is segmented by the drug (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), by brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia) and by geography.

    Reasons for Buying Glucagon like Peptide 1 (GLP – 1) Agonists Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999732

    Key Market Trends: – Constant Global Trend of High Diabetes Prevalence

    The sales of GLP-1 are directly proportional to the global trend of high diabetes prevalence.
    For instance, the percentages of type 2 diabetes in a few significant countries are as follows: China 22.8%, Oman 17.2%, Malaysia 12.9%, and so on.
    It is estimated, worldwide, that approximately USD 8.39 billion is spent on diabetes. The growth in the number of middle-class households, as well as increasing per capita income in these countries, are expected to result in better spending power in general, thereby helping to drive the market during the forecast period (2019-2024).
    Along with this, a few critical factors, such as advanced healthcare infrastructure, technological advancement, and availability of skilled medical professionals, are likely to play paradigm shifting roles in the overall growth of this market.

    North America to Dominate the Market in Terms of Revenue

    North America accounts for 77% of the overall GLP-1 market and is expected to witness a growth rate of 6.53%, during the forecast period.
    In the Middle East & Africa, the GLP-1 market is expected to see high growth during the forecast period, with a CAGR of 25.08%.
    In Asia-Pacific, according to the International Diabetes Federation, Japan and Australia have the highest per capita expenditure, of upwards of USD 3,000. However, China and India have the highest diabetes prevalence.

    Glucagon like Peptide 1 (GLP – 1) Agonists Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 5000 USD for single user license) – https://www.industryresearch.co/purchase/13999732

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Glucagon like Peptide 1 (GLP – 1) Agonists Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Exenatide
    5.1.1.1 Byetta (Value and Volume 2012-2024)
    5.1.1.2 Bydureon (Value and Volume 2012-2024)
    5.1.2 Liraglutide
    5.1.2.1 Victoza (Value and Volume 2012-2024)
    5.1.3 Lixisenatide
    5.1.3.1 Lyxumia (Value and Volume 2012-2024)
    5.1.4 Dulaglutide
    5.1.4.1 Trulicity (Value and Volume 2012-2024)
    5.2 Geography
    5.2.1 North America
    5.2.1.1 US (Value and Volume 2012-2024)
    5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.2 Canada (Value and Volume 2012-2024)
    5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.1.3 Rest of North America (Value and Volume 2012-2024)
    5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.1.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2 Europe
    5.2.2.1 Germany (Value and Volume 2012-2024)
    5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.2 Spain (Value and Volume 2012-2024)
    5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.3 Italy (Value and Volume 2012-2024)
    5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.4 France (Value and Volume 2012-2024)
    5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.5 UK (Value and Volume 2012-2024)
    5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.6 Russia (Value and Volume 2012-2024)
    5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
    5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.2.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3 Asia-Pacific
    5.2.3.1 Japan (Value and Volume 2012-2024)
    5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.2 China (Value and Volume 2012-2024)
    5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.3 Australia (Value and Volume 2012-2024)
    5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.4 India (Value and Volume 2012-2024)
    5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.5 South Korea (Value and Volume 2012-2024)
    5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.6 Malaysia (Value and Volume 2012-2024)
    5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.7 Indonesia (Value and Volume 2012-2024)
    5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.7.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.8 Thailand (Value and Volume 2012-2024)
    5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.8.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.9 Philippines (Value and Volume 2012-2024)
    5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.9.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)
    5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.3.10.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4 Latin America
    5.2.4.1 Brazil (Value and Volume 2012-2024)
    5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4.2 Mexico (Value and Volume 2012-2024)
    5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)
    5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.4.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5 Middle East & Africa
    5.2.5.1 South Africa (Value and Volume 2012-2024)
    5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.1.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)
    5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.2.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.3 Oman (Value and Volume 2012-2024)
    5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.3.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.4 Egypt (Value and Volume 2012-2024)
    5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.4.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.5 Iran (Value and Volume 2012-2024)
    5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.5.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)
    5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)
    5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
    5.2.5.6.2 By Company (Novo Nordisk, Sanofi, Eli Lilly, and AstraZeneca)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 COMPANY PROFILES
    7.1.1 Novo Nordisk
    7.1.2 Sanofi
    7.1.3 Eli Lilly
    7.1.4 AstraZeneca
    7.2 MARKET SHARE ANALYSIS
    7.2.1 Novo Nordisk
    7.2.2 Sanofi
    7.2.3 Eli Lilly
    7.2.4 AstraZeneca

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Cam Chain Market 2019 | Worldwide Industry Trends, Share, Gross Margin, Size, Future Demand, Analysis by Top Leading Player and Forecast till 2024

    Consumer Food Delivery Market 2019 Industry Global Trends, Size, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2024

    Global Nasopharyngeal Cancer Market 2019 Upstream Raw Materials and Equipment with Manufacturing Process 2024

    Electric Household Appliances Market Size and Share Analysis 2019: Report Contains R&D, Designing, Manufacturing and Forecast Model 2025